APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Waldenstrom Macroglobulinemia Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Waldenstrom Macroglobulinemia Therapeutics Market Outlook and Growth Opportunities 2026

Report ID 174047290426 December 2025192 pages

Choose your research edition.

Industry ResearchWaldenstrom Macroglobulinemia Therapeutics Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Waldenstrom Macroglobulinemia Therapeutics Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Waldenstrom Macroglobulinemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Waldenstrom Macroglobulinemia Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Waldenstrom Macroglobulinemia Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Waldenstrom Macroglobulinemia Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Waldenstrom Macroglobulinemia Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Waldenstrom Macroglobulinemia Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Waldenstrom Macroglobulinemia Therapeutics market include Merck KGaA, Millennium Pharmaceuticals, Inc., Karyopharm Therapeutics, Inc., Incyte Corporation, IGF Oncology, LLC., Idera Pharmaceuticals, Inc., Hutchison MediPharma Limited, Gilead Sciences, Inc. and Genmab A/S, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Waldenstrom Macroglobulinemia Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Waldenstrom Macroglobulinemia Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Waldenstrom Macroglobulinemia Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Waldenstrom Macroglobulinemia Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

Waldenstrom Macroglobulinemia Therapeutics Segment by Company

Merck KGaA

Millennium Pharmaceuticals, Inc.

Karyopharm Therapeutics, Inc.

Incyte Corporation

IGF Oncology, LLC.

Idera Pharmaceuticals, Inc.

Hutchison MediPharma Limited

Gilead Sciences, Inc.

Genmab A/S

Genentech, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

BeiGene(Beijing) Co.,Ltd

Waldenstrom Macroglobulinemia Therapeutics Segment by Type

CB-839

DI-B4

FV-162

Entospletinib

Copanlisib Hydrochloride

Everolimus

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Application

Clinic

Hospital

Others

Waldenstrom Macroglobulinemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Waldenstrom Macroglobulinemia Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Waldenstrom Macroglobulinemia Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Waldenstrom Macroglobulinemia Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Waldenstrom Macroglobulinemia Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Waldenstrom Macroglobulinemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Waldenstrom Macroglobulinemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Waldenstrom Macroglobulinemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Waldenstrom Macroglobulinemia Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Waldenstrom Macroglobulinemia Therapeutics industry.

Chapter 3: Detailed analysis of Waldenstrom Macroglobulinemia Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Waldenstrom Macroglobulinemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Waldenstrom Macroglobulinemia Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Waldenstrom Macroglobulinemia Therapeutics Industry Trends Table 2. Waldenstrom Macroglobulinemia Therapeutics Industry Drivers Table 3. Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges Table 4. Waldenstrom Macroglobulinemia Therapeutics Industry Restraints Table 5. Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Waldenstrom Macroglobulinemia Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global Waldenstrom Macroglobulinemia Therapeutics Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Waldenstrom Macroglobulinemia Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Waldenstrom Macroglobulinemia Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global Waldenstrom Macroglobulinemia Therapeutics Company, Product Type & Application Table 13. Global Waldenstrom Macroglobulinemia Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Waldenstrom Macroglobulinemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CB-839 Table 18. Significant Companies of DI-B4 Table 19. Significant Companies of FV-162 Table 20. Significant Companies of Entospletinib Table 21. Significant Companies of Copanlisib Hydrochloride Table 22. Significant Companies of Everolimus Table 23. Significant Companies of Others Table 24. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Type (2021-2026) & (W Units) Table 26. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Type (2027-2032) & (W Units) Table 27. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Type (2021-2026) Table 28. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Type (2027-2032) Table 29. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type (2021-2026) Table 33. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Clinic Table 35. Significant Companies of Hospital Table 36. Significant Companies of Others Table 37. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Application (2021-2026) & (W Units) Table 39. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Application (2027-2032) & (W Units) Table 40. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Application (2021-2026) Table 41. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Application (2027-2032) Table 42. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application (2021-2026) Table 46. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application (2027-2032) Table 47. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2026) & (W Units) Table 49. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region (2021-2026) Table 50. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2027-2032) & (W Units) Table 51. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region (2027-2032) Table 52. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Region (2021-2026) Table 55. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Region (2027-2032) Table 57. Global Waldenstrom Macroglobulinemia Therapeutics Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Waldenstrom Macroglobulinemia Therapeutics Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026) & (W Units) Table 62. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2021-2026) Table 63. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032) & (W Units) Table 64. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Country (2027-2032) Table 65. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Market Share by Country (2021-2026) Table 67. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Market Share by Country (2027-2032) Table 69. Merck KGaA Company Information Table 70. Merck KGaA Business Overview Table 71. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 73. Merck KGaA Recent Development Table 74. Millennium Pharmaceuticals, Inc. Company Information Table 75. Millennium Pharmaceuticals, Inc. Business Overview Table 76. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 78. Millennium Pharmaceuticals, Inc. Recent Development Table 79. Karyopharm Therapeutics, Inc. Company Information Table 80. Karyopharm Therapeutics, Inc. Business Overview Table 81. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 83. Karyopharm Therapeutics, Inc. Recent Development Table 84. Incyte Corporation Company Information Table 85. Incyte Corporation Business Overview Table 86. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 88. Incyte Corporation Recent Development Table 89. IGF Oncology, LLC. Company Information Table 90. IGF Oncology, LLC. Business Overview Table 91. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 93. IGF Oncology, LLC. Recent Development Table 94. Idera Pharmaceuticals, Inc. Company Information Table 95. Idera Pharmaceuticals, Inc. Business Overview Table 96. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 98. Idera Pharmaceuticals, Inc. Recent Development Table 99. Hutchison MediPharma Limited Company Information Table 100. Hutchison MediPharma Limited Business Overview Table 101. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 103. Hutchison MediPharma Limited Recent Development Table 104. Gilead Sciences, Inc. Company Information Table 105. Gilead Sciences, Inc. Business Overview Table 106. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 108. Gilead Sciences, Inc. Recent Development Table 109. Genmab A/S Company Information Table 110. Genmab A/S Business Overview Table 111. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 113. Genmab A/S Recent Development Table 114. Genentech, Inc. Company Information Table 115. Genentech, Inc. Business Overview Table 116. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 118. Genentech, Inc. Recent Development Table 119. Celgene Corporation Company Information Table 120. Celgene Corporation Business Overview Table 121. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 123. Celgene Corporation Recent Development Table 124. Calithera Biosciences, Inc. Company Information Table 125. Calithera Biosciences, Inc. Business Overview Table 126. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 128. Calithera Biosciences, Inc. Recent Development Table 129. BeiGene(Beijing) Co.,Ltd Company Information Table 130. BeiGene(Beijing) Co.,Ltd Business Overview Table 131. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio Table 133. BeiGene(Beijing) Co.,Ltd Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Waldenstrom Macroglobulinemia Therapeutics Distributors List Table 137. Waldenstrom Macroglobulinemia Therapeutics Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Waldenstrom Macroglobulinemia Therapeutics Product Image Figure 2. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Waldenstrom Macroglobulinemia Therapeutics Sales (2021-2032) & (W Units) Figure 5. Global Waldenstrom Macroglobulinemia Therapeutics Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Waldenstrom Macroglobulinemia Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CB-839 Image Figure 10. DI-B4 Image Figure 11. FV-162 Image Figure 12. Entospletinib Image Figure 13. Copanlisib Hydrochloride Image Figure 14. Everolimus Image Figure 15. Others Image Figure 16. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Type (2021-2032) Figure 19. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type (2021-2032) Figure 22. Clinic Image Figure 23. Hospital Image Figure 24. Others Image Figure 25. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Application (2021-2032) Figure 28. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application (2021-2032) Figure 31. Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 32. Global Waldenstrom Macroglobulinemia Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 36. North America Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 42. South America Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Waldenstrom Macroglobulinemia Therapeutics Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Waldenstrom Macroglobulinemia Therapeutics Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • CB-839
  • DI-B4
  • FV-162
  • Entospletinib
  • Copanlisib Hydrochloride
  • Everolimus
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Karyopharm Therapeutics, Inc.
  • Incyte Corporation
  • IGF Oncology, LLC.
  • Idera Pharmaceuticals, Inc.
  • Hutchison MediPharma Limited
  • Gilead Sciences, Inc.
  • Genmab A/S
  • Genentech, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • BeiGene(Beijing) Co.,Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Waldenstrom Macroglobulinemia Therapeutics Market Dynamics
  1. 2.1 Waldenstrom Macroglobulinemia Therapeutics Industry Trends
  2. 2.2 Waldenstrom Macroglobulinemia Therapeutics Industry Drivers
  3. 2.3 Waldenstrom Macroglobulinemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Waldenstrom Macroglobulinemia Therapeutics Industry Restraints
3 Waldenstrom Macroglobulinemia Therapeutics Market by Company
  1. 3.1 Global Waldenstrom Macroglobulinemia Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Waldenstrom Macroglobulinemia Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global Waldenstrom Macroglobulinemia Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global Waldenstrom Macroglobulinemia Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global Waldenstrom Macroglobulinemia Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global Waldenstrom Macroglobulinemia Therapeutics Company Product Type and Application
  8. 3.8 Global Waldenstrom Macroglobulinemia Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Waldenstrom Macroglobulinemia Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Waldenstrom Macroglobulinemia Therapeutics Market by Type
  1. 4.1 Waldenstrom Macroglobulinemia Therapeutics Type Introduction
  2. 4.1.1 CB-839
  3. 4.1.2 DI-B4
  4. 4.1.3 FV-162
  5. 4.1.4 Entospletinib
  6. 4.1.5 Copanlisib Hydrochloride
  7. 4.1.6 Everolimus
  8. 4.1.7 Others
  9. 4.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Type
  10. 4.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Type
  14. 4.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Type (2021-2032)
  16. 4.3.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type (2021-2032)
5 Waldenstrom Macroglobulinemia Therapeutics Market by Application
  1. 5.1 Waldenstrom Macroglobulinemia Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Application
  6. 5.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Application
  10. 5.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application (2021-2032)
6 Waldenstrom Macroglobulinemia Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global Waldenstrom Macroglobulinemia Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Waldenstrom Macroglobulinemia Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Waldenstrom Macroglobulinemia Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Waldenstrom Macroglobulinemia Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Waldenstrom Macroglobulinemia Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck KGaA
  2. 8.1.1 Merck KGaA Company Information
  3. 8.1.2 Merck KGaA Business Overview
  4. 8.1.3 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  6. 8.1.5 Merck KGaA Recent Developments
  7. 8.2 Millennium Pharmaceuticals, Inc.
  8. 8.2.1 Millennium Pharmaceuticals, Inc. Company Information
  9. 8.2.2 Millennium Pharmaceuticals, Inc. Business Overview
  10. 8.2.3 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Millennium Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  12. 8.2.5 Millennium Pharmaceuticals, Inc. Recent Developments
  13. 8.3 Karyopharm Therapeutics, Inc.
  14. 8.3.1 Karyopharm Therapeutics, Inc. Company Information
  15. 8.3.2 Karyopharm Therapeutics, Inc. Business Overview
  16. 8.3.3 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Karyopharm Therapeutics, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  18. 8.3.5 Karyopharm Therapeutics, Inc. Recent Developments
  19. 8.4 Incyte Corporation
  20. 8.4.1 Incyte Corporation Company Information
  21. 8.4.2 Incyte Corporation Business Overview
  22. 8.4.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  24. 8.4.5 Incyte Corporation Recent Developments
  25. 8.5 IGF Oncology, LLC.
  26. 8.5.1 IGF Oncology, LLC. Company Information
  27. 8.5.2 IGF Oncology, LLC. Business Overview
  28. 8.5.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  30. 8.5.5 IGF Oncology, LLC. Recent Developments
  31. 8.6 Idera Pharmaceuticals, Inc.
  32. 8.6.1 Idera Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Idera Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Idera Pharmaceuticals, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  36. 8.6.5 Idera Pharmaceuticals, Inc. Recent Developments
  37. 8.7 Hutchison MediPharma Limited
  38. 8.7.1 Hutchison MediPharma Limited Company Information
  39. 8.7.2 Hutchison MediPharma Limited Business Overview
  40. 8.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  42. 8.7.5 Hutchison MediPharma Limited Recent Developments
  43. 8.8 Gilead Sciences, Inc.
  44. 8.8.1 Gilead Sciences, Inc. Company Information
  45. 8.8.2 Gilead Sciences, Inc. Business Overview
  46. 8.8.3 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Gilead Sciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  48. 8.8.5 Gilead Sciences, Inc. Recent Developments
  49. 8.9 Genmab A/S
  50. 8.9.1 Genmab A/S Company Information
  51. 8.9.2 Genmab A/S Business Overview
  52. 8.9.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  54. 8.9.5 Genmab A/S Recent Developments
  55. 8.10 Genentech, Inc.
  56. 8.10.1 Genentech, Inc. Company Information
  57. 8.10.2 Genentech, Inc. Business Overview
  58. 8.10.3 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Genentech, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  60. 8.10.5 Genentech, Inc. Recent Developments
  61. 8.11 Celgene Corporation
  62. 8.11.1 Celgene Corporation Company Information
  63. 8.11.2 Celgene Corporation Business Overview
  64. 8.11.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  66. 8.11.5 Celgene Corporation Recent Developments
  67. 8.12 Calithera Biosciences, Inc.
  68. 8.12.1 Calithera Biosciences, Inc. Company Information
  69. 8.12.2 Calithera Biosciences, Inc. Business Overview
  70. 8.12.3 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Calithera Biosciences, Inc. Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  72. 8.12.5 Calithera Biosciences, Inc. Recent Developments
  73. 8.13 BeiGene(Beijing) Co.,Ltd
  74. 8.13.1 BeiGene(Beijing) Co.,Ltd Company Information
  75. 8.13.2 BeiGene(Beijing) Co.,Ltd Business Overview
  76. 8.13.3 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 BeiGene(Beijing) Co.,Ltd Waldenstrom Macroglobulinemia Therapeutics Product Portfolio
  78. 8.13.5 BeiGene(Beijing) Co.,Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Waldenstrom Macroglobulinemia Therapeutics Value Chain Analysis
  2. 9.1.1 Waldenstrom Macroglobulinemia Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Waldenstrom Macroglobulinemia Therapeutics Sales Mode & Process
  6. 9.2 Waldenstrom Macroglobulinemia Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Waldenstrom Macroglobulinemia Therapeutics Distributors
  9. 9.2.3 Waldenstrom Macroglobulinemia Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst